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SPECIAL ARTICLE
Use of Erythropoietin in Cancer Patients:
Assessment of Oncologists’ Practice Patterns in the
United States and Other Countries
Jared R. Adams, Linda S. Elting, PhD, Gary H. Lyman, MD, James N. George, MD,
Barry C. Lembersky, MD, James O. Armitage, MD, George D. Demetri, MD,
Charles L. Bennett, MD, PhD
PURPOSE: To assess physician use of erythropoietin in cancer
patients before publication of the American Society of Clinical
Oncology/American Society of Hematology guidelines.
METHODS: Questionnaires about erythropoietin use in prac-
tice and 12 hypothetical clinical scenarios involving patients
with cancer were mailed to 2000 oncologists/hematologists in
the United States and 19 other countries. Response rates were
30% in the United States and 25% internationally. Data on
erythropoietin use for ovarian cancer were obtained from one
clinical trial. Multivariate regression models assessed predictors
of erythropoietin prescription.
RESULTS: Most physicians selected a hemoglobin level 10
g/dL as an upper threshold for erythropoietin use (36% to 51%
of U.S. physicians and 21% to 32% of foreign physicians). Fre-
quent erythropoietin use (defined as use in at least 10% of can-
cer patients) was higher in the United States than elsewhere
(adjusted odds ratio [OR] 5.8; 95% confidence interval [CI]:
2.5 to 13.4). Among U.S. physicians, those who said they used
erythropoietin frequently were more likely to be in fee-for-ser-
vice than managed care settings (OR 2.2; 95% CI: 1.3 to 3.7).
Those who reported never using erythropoietin practiced in
countries that had lower annual per capita health care expendi-
tures, lower proportions of privately funded health care, and a
national health service (P 0.05 for all comparisons). Of 235
ovarian cancer patients who received topotecan, 38% (45/118)
of U.S. patients and 2% (2/117) of European patients who de-
veloped grade 1 anemia (hemoglobin level between 10 and 12
g/dL) were treated with erythropoietin (P0.01).
CONCLUSION: Financial considerations and a hemoglobin
level 10 g/dL appear to influence erythropoietin use in the
United States, whereas financial considerations alone deter-
mine erythropoietin use abroad. Am J Med. 2004;116:28 –34.
©2004 by Excerpta Medica Inc.
Recombinant human erythropoietin increases redblood cell count and hemoglobin concentrationin patients who have anemia associated with can-
cer or its treatment (1). However, erythropoietin is ex-
pensive and optimal treatment is not known (2). The
American Society of Clinical Oncology and the American
Society of Hematology jointly requested that the Agency
for Healthcare Research and Quality review the use of
erythropoietin in oncology and develop guidelines on the
subject. The Agency also provided a grant for surveying
oncologist preferences for erythropoietin use before pub-
lication of the review.
The American Society of Clinical Oncology previously
addressed concerns about the benefits of granulocyte and
granulocyte-macrophage colony-stimulating factors (3–
6). It surveyed oncologists’ preferences for growth factor
use and subsequently published evidence-based guide-
lines (3,7–9). A follow-up survey found that support for
these agents decreased in settings that were not supported
by the guidelines (8). However, these evaluations did not
address international considerations and data on actual
patterns of use. We therefore sought to evaluate the pref-
erences of oncologists in the United States and other
countries regarding erythropoietin use and to provide
data on actual patterns of care.
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METHODS
Surveys
A random sample of 1500 physicians who practiced in the
United States was selected from the American Society of
Clinical Oncology membership list and a random sample
of 500 physicians who practiced in 19 countries in Eu-
rope, Asia, Africa, and the Americas was selected from the
Multinational Association for Supportive Care of Cancer
membership list. Subjects who failed to respond received
a second mailing. Potential respondents who spent fewer
than 5 hours per week in practice were instructed to re-
turn the questionnaire unanswered. The survey ad-
dressed erythropoietin use in 12 hypothetical clinical sce-
narios in the settings of sarcoma, Hodgkin’s disease, and
cervical, breast, and ovarian cancer. Vignettes addressed
erythropoietin use before, during, and after therapy in
fatigued and nonfatigued patients. Physicians were al-
lowed to respond to a vignette that was outside their clin-
ical experience. Support for erythropoietin use was de-
fined as reported use in10% of patients. The survey also
included questions on the frequency of erythropoietin
use, effect of reimbursement, and whether there were in-
stitutional guidelines on erythropoietin use. Information
was also obtained on sociodemographic characteristics,
including specialty, year of graduation from medical
school, practice setting, number of years in practice, and
average number of cancer patients seen per week.
Multivariate regression was used to assess factors asso-
ciated with reported frequent erythropoietin use. The
median physician-reported percentage of patients who
were prescribed erythropoietin (10%, 10% or more)
was the dependent variable in the model. Independent
predictors included practice setting (private fee-for-ser-
vice, group-staff health maintenance organization
[HMO], or academic group), practice type (oncology,
hematology, hematology and oncology), medical school
graduation year (1970, 1970 or later), local erythropoi-
etin guidelines (yes/no), patients seen per week (50, 50
or more), reimbursement denials, and privately funded
versus social health care systems.
Because information about practice setting (academic,
HMO, private fee-for-service) was not applicable to phy-
sicians in other countries, a second analysis assessed the
influence of the amount, source, and structure of health
care financing for each country on support for erythro-
poietin use. Multinomial logistic regression was used to
identify factors associated with the extremes of practice
(always or never using erythropoietin in all 12 vignettes)
as compared with a strategy dependent on the clinical setting
and hemoglobin level (occasional users). A multilevel model
was fit, with physician subjects nested within countries.
Candidate factors included sex, practice type, years since
graduation, specialty, guideline availability, as well as coun-
try-specific information about annual per capita health care
expenditure, percentage of health care funded publicly, and
the presence of a national health care insurance system (10).
Analyses were performed with SAS, version 8.1 (SAS Insti-
tute, Cary, North Carolina) using the GENMOD (General
Estimating Equations) procedure with an independent co-
variance matrix.
Patterns of Use
Data on patterns of use were evaluated for physicians who
provided care for women with ovarian cancer, based on
usage data obtained from a phase 3, multicenter, ran-
domized controlled trial conducted in the United States
and the United Kingdom between 1997 to 1999 that in-
volved 474 ovarian cancer patients with relapsed or re-
fractory ovarian cancer, all of whom had failed first-line
chemotherapy with a platinum-based regimen (11). The
study drug regimens consisted of either pegylated liposo-
mal doxorubicin (a 1-hour intravenous infusion of 50
mg/m2 every 28 days) or topotecan (a 30-minute infusion
of 1.5 mg/m2/d for 5 consecutive days every 21 days).
Approximately half of the patients were treated in the
United States and the remaining were treated in Europe.
Patient-level data were collected prospectively at the time
of erythropoietin prescription during chemotherapy, he-
moglobin level at the time of erythropoietin prescription,
and duration of erythropoietin administration. During
the trial, 28% (66/235) of patients who were taking topo-
tecan experienced grade 3 or 4 anemia (defined as a he-
moglobin level 8 g/dL) versus 5% (12/239) who were
taking doxorubicin.
RESULTS
The response rate for the survey was 30% (332/1108) in
the United States and 25% (88/355) internationally.
More than half of U.S. respondents practiced in fee-for-
service settings, about one third were in academic prac-
tices, and about 15% were in HMO practices (Table 1).
About one quarter followed formal erythropoietin guide-
lines or practiced in settings where guidelines were per-
ceived to influence practice, and approximately half were
hematologist/oncologists (Table 1). More physicians in
the United States than in other countries reported eryth-
ropoietin use in more than 5 patients per week (53%
[167/316] vs. 10% [8/80]).
Physicians in the United States reported that they pre-
scribed erythropoietin to about 20% of cancer patients
(vs. 8% internationally). Based on the responses to the
clinical vignettes, patterns of erythropoietin use were
similar among treatment regimens associated with cur-
able versus incurable malignancies (Table 2). Physicians
were most supportive of using erythropoietin during che-
motherapy versus either before initiating or after comple-
tion of chemotherapy. The maximum hemoglobin
threshold for erythropoietin use was most often 10 g/dL.
Across clinical vignettes, physicians were consistent
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about whether they never used erythropoietin, or sup-
ported erythropoietin prophylaxis, i.e., in patients with
hemoglobin levels12 g/dL.
In the United States, several factors were associated
with frequent (10%) prescribing of erythropoietin, in-
cluding being a hematologist/oncologist (adjusted odds
ratio [OR]  1.6; 95% confidence interval [CI]: 2.5 to
13.4) and practicing in a fee-for-service setting (OR 
2.2; 95% CI: 1.3 to 3.7). Frequent erythropoietin use was
much higher in the United States than in other countries
(OR 5.8; 95% CI: 2.5 to 13.4). Physicians in the United
States showed a greater preference for erythropoietin use,
particularly before initiating chemotherapy in patients
with ovarian cancer (68% [198/295] vs. 42% [34/80]), at
any hemoglobin threshold during treatment (95% [292/
308] vs. 68% [54/80]), after treatment in patients with
stable disease (82% [254/308] vs. 48% [38/80]), and for
ever use (94% [289/308] vs. 68% [54/80]; P 0.001 for
each comparison).
Of U.S. respondents, 37% (108/315) reported that fi-
nancial considerations had affected the decision to use
erythropoietin at least once in their practice. Physicians
in fee-for-service settings (OR 3.0; 95% CI: 1.6 to 5.5)
and who prescribed erythropoietin frequently (OR 1.9;
95% CI: 1.1 to 3.4) were most likely to have withheld
erythropoietin treatment because of reimbursement con-
siderations. Physicians who reported never using eryth-
ropoietin were more likely to practice in countries where
the annual per capita health care expenditure was low,
where a large proportion of health care costs was funded
from public sources, and where there was a national
health insurance program (Table 3; P0.05 for each pa-
rameter). The opposite was true of physicians who always
supported the use of erythropoietin (Table 3).
Patterns of Erythropoietin Use in Ovarian Cancer
In the clinical trial of second-line chemotherapy with to-
potecan or doxorubicin in patients with ovarian cancer,
no topotecan-treated patient received erythropoietin be-
fore the initiation of the first cycle of treatment. Of topo-
tecan-treated patients, 38% (45/118) of U.S. patients ver-
sus 2% (2/117) of European patients were treated with
erythropoietin (P0.01). Physicians in the United States
frequently initiated erythropoietin treatment during the
third cycle of topotecan chemotherapy, often following
one to two cycles of anemia. At the time of erythropoietin
initiation, 27% (n 33) of patients in the United States
had a hemoglobin level between 10 and 12 g/dL, 62% (n
 73) had a level between 8 and 10 g/dL, and 10% (n
12) had a level8 g/dL. The most common hemoglobin
level at erythropoietin prescription was 9.5 g/dL. The av-
erage duration of erythropoietin use was 16 weeks during
the entire course of therapy for patients who were treated
in the United States. Due to the low incidence of anemia
in the pegylated liposomal doxorubicin arm, erythropoi-
etin use was lower. Of all 474 enrolled ovarian cancer
patients, 37% (56/150) of U.S. patients and 2% (2/122) of
European patients who developed any grade anemia (he-
moglobin12 g/dL) were treated with erythropoietin (P
 6.01).
DISCUSSION
Erythropoietin improves hemoglobin levels and reduces
transfusion requirements among cancer patients
(2,12,13). Its use remains controversial, however, partly
because of the paucity of data to support a quality-of-life
or survival benefit (12,13). Moreover, it is unclear how
much value any health care system places on subjective
patient-reported endpoints such as quality-of-life pa-
rameters. Our results indicate that oncologists in the
United States support erythropoietin use in cancer pa-
tients who have a serum hemoglobin level 10 g/dL,
whereas oncologists in other countries are far less sup-
portive of its use in this setting. Moreover, U.S. oncolo-
Table 1. Demographic and Practice Characteristics of Physicians from the United States and Other Countries Who Participated in
the Erythropoietin Survey
Characteristic
Physicians in the United States
(n 332)
Physicians in Other Countries
(n 88)
Number (%)
Type of practice
Academic 91 (27) Not available
Health maintenance organization 49 (14) Not applicable
Fee-for-service 198 (59) Not applicable
Medical school graduation before 1970 76 (23) 18 (20)
See50 cancer patients per week 232 (70) 44 (50)
Hematology/oncology 161 (50) 27 (33)
Work with formal erythropoietin practice guideline 85 (25) 16 (18)
Order erythropoietin for5 patients per week* 167 (53) 8 (10)
* Percentages based on 316 physicians in the United States and 80 physicians in other countries.
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Table 2. Maximum Hemoglobin Threshold for Prescription of Erythropoietin among Surveyed Oncologists Who Practiced in the United States or Other Countries
Hemoglobin
Threshold
Setting for Clinical Practice
Hodgkin’s Disease
Cervical
Cancer Breast Cancer Ewing Sarcoma Ovarian Cancer
Before
Chemotherapy
Before
Cycle 2
After
Therapy
Any
Point
Before
Chemotherapy
Before
Cycle 3 3 Months 6 Months
Before
Chemotherapy
Before
Cycle 2
After Stable
Disease
After Progressive
Disease
United States
(n 332)
(n 298) (n 308) (n 306) (n 296) (n 306) (n 314) (n 300) (n 304) (n 295) (n 308) (n 310) (n 308)
12 g/dL 6 (2) 18 (6) 15 (5) 18 (6) 12 (4) 28 (9) 18 (6) 36 (12) 12 (4) 22 (7) 16 (5) 22 (7)
11 g/dL 36 (12) 59 (19) 40 (13) 50 (17) 55 (18) 79 (25) 42 (14) 64 (21) 53 (18) 65 (21) 37 (12) 59 (19)
10 g/dL 149 (50) 126 (41) 110 (36) 112 (38) 144 (47) 132 (42) 105 (35) 116 (38) 130 (44) 132 (43) 118 (38) 142 (46)
9 g/dL 0 68 (22) 64 (21) 56 (19) 0 53 (17) 69 (23) 61 (20) 0 55 (18) 56 (18) 59 (19)
8 g/dL 0 18 (6) 28 (9) 9 (3) 0 9 (3) 33 (11) 9 (6) 0 18 (6) 31 (10) 9 (3)
No erythropoietin 107 (36) 18 (6) 49 (16) 50 (17) 95 (31) 13 (4) 33 (11) 9 (3) 100 (34) 15 (5) 53 (17) 18 (6)
Other Countries
(n 88)
(n 72) (n 78) (n 77) (n 79) (n 75) (n 80) (n 75) (n 75) (n 78) (n 80) (n 80) (n 80)
12 g/dL 1 (1) 2 (3) 2 (3) 2 (3) 4 (5) 4 (5) 5 (7) 6 (8) 4 (5) 5 (6) 2 (3) 5 (6)
11 g/dL 4 (6) 7 (9) 5 (7) 15 (19) 9 (12) 14 (17) 9 (12) 14 (19) 9 (12) 12 (15) 7 (9) 10 (12)
10 g/dL 19 (27) 20 (26) 15 (20) 15 (19) 24 (32) 24 (30) 20 (26) 19 (25) 18 (23) 19 (24) 16 (20) 25 (31)
9 g/dL 0 17 (22) 10 (13) 1 (1) 0 8 (10) 11 (15) 17 (22) 0 10 (12) 9 (11) 11 (14)
8 g/dL 0 6 (8) 9 (12) 4 (5) 0 4 (5) 8 (11) 5 (6) 0 10 (8) 3 (4) 4 (5)
No erythropoietin 48 (66) 25 (32) 35 (45) 42 (53) 38 (51) 26 (33) 22 (29) 15 (20) 47 (60) 26 (33) 42 (53) 26 (32)
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gists who practice in fee-for-service settings are more
likely than those who practice in managed care settings to
support erythropoietin use. Overall, higher support for
erythropoietin use was associated with several country-
level factors, including higher levels of private medicine,
the absence of national health insurance programs, and
larger global health budgets.
Economic and clinical considerations appear to influ-
ence the decision to use erythropoietin. Evidence-based
reviews and guidelines are most supportive of erythro-
poietin use in chemotherapy patients who have hemoglo-
bin levels10 g/dL (2,12,13), which was also the setting
in which U.S. survey respondents and U.S. oncologists in
the ovarian cancer study were most likely to support
erythropoietin use. In contrast, physicians in other coun-
tries were less supportive of erythropoietin use. These
differences have economic implications. For example, the
mean cost of anemia treatment for patients who received
topotecan in the ovarian cancer study was $3507 greater
in the United States than in Europe ($4839 vs. $1432),
primarily because of international differences in expen-
ditures on erythropoietin per patient (mean of $3490 vs.
$242), whereas expenditures for packed red blood cells
were similar ($1346 vs. $1190) (14). However, overall
survival rates, disease-free survival rates, and quality-of-
life outcomes were virtually identical for the ovarian can-
cer patients who received care in the United States versus
Europe (11). Almost two thirds of erythropoietin use for
patients who received care in the United States occurred
among women with a hemoglobin level10 g/dL, which
is similar to the 67% rate reported by U.S. oncologists in
our survey. Furthermore, the preference to use erythro-
poietin in cancer patients with mild anemia in the United
States is consistent with Medicare reimbursement poli-
cies. In fact, reimbursement policies could be a major
determinant of the practice patterns and preferences of
physicians. Almost all of the state Medicare carriers re-
quire documentation of a hemoglobin level 10 g/dL
before reimbursing for erythropoietin use. In other coun-
tries, reimbursement policies for erythropoietin differ
markedly. We found significantly lower levels of support
for erythropoietin use among respondents from coun-
tries that have national health insurance programs, large
publicly funded health care systems, or low per capita
health care expenditures.
The study design addressed limitations identified in
previous surveys of colony-stimulating factor use. Data
on patterns of use were obtained to complement the sur-
vey scenario for women with ovarian cancer. The clinical
trial results and the survey both identified infrequent use
of erythropoietin before initiation of the first cycle of che-
motherapy, infrequent use of prophylactic erythropoie-
tin for patients who were not anemic, and use for ovarian
cancer in almost two thirds of patients after hemoglobin
levels decreased to10 g/dL. The survey results and data
on patterns of use also included assessments from inter-
national settings. Researchers from France and the
United States previously identified greater use of cyto-
kines in the clinical practice setting in the United States
than in France (15,16), which is similar to that reported in
the current study.
The survey findings indicate that support for erythro-
poietin use in the United States was higher in the fee-for-
service than managed care setting, mirroring that which
has been reported previously for other cytokines. Physi-
cians in the fee-for-service setting more often supported
the use of erythropoietin and granulocyte and granulo-
cyte-macrophage colony-stimulating factor for each of
the clinical scenarios than did managed care physicians.
The surveys also showed greater support among fee-for-
service physicians for use of colony-stimulating factors in
the setting of curative and palliative treatments and in
Table 3. Erythropoietin Use, by Type of Health Care Financing*
Health Care Financing Parameter†
Never Use
Erythropoietin
(n 26)
Always Use
Erythropoietin
(n 189)
Sometimes Use
Erythropoietin
(n 205) P Value‡
Number (%)
Annual per capita health care expenditure 0.02
$1000 13 (50) 18 (9) 42 (20)
$1000–$3000 4 (15) 1 (1) 12 (6)
$3000 9 (35) 170 (90) 151 (74)
National health insurance program 16 (60) 19 (10) 60 (28) 0.04
Public funding for health care 0.001
0%–50% 10 (39) 169 (89) 143 (70)
50% 16 (61) 20 (11) 62 (30)
* Based on entire data set including all countries. A nested regression model was used to adjust for clustering by country.
† Data from the World Health Organization (10).
‡ P values calculated by multilevel multinomial logistic regression. Additional covariates in the model included sex, practice type, years since
graduation, specialty, and guideline availability.
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persons with solid tumors, leukemia, and lymphoma (7–
9). Although it is not known if reimbursement consider-
ations can partly explain these variations in cytokine use,
respondents to both surveys on erythropoietin and colo-
ny-stimulating factor use reported that reimbursement
denials were common.
Lastly, the issues identified in this study regarding
erythropoietin use—the high variation in prescription
rates, the large potential economic impact of chronic
overuse, the uncertainty about optimal treatment, and
the identification of ethical considerations—may be use-
ful in directing evidence-based clinical guidelines. The
purpose of this study was to measure baseline practice
variations and predictors of overuse before the release of
the American Society of Clinical Oncology/American So-
ciety of Hematology guidelines to possibly target dissem-
ination and assess efficacy of guideline publication. The
guideline panel supported erythropoietin use as a treat-
ment option for patients with chemotherapy-associated
anemia who had a hemoglobin level 10 g/dL (Appen-
dix). Use of erythropoietin in patients with “less severe
anemia (hemoglobin 12 g/ dL but never below 10
g/dL). . .should be determined by clinical circumstances”
(17). We found that 38% of erythropoietin prescription
occurred before hemoglobin levels crossed the cutoff of
10 g/dL, indicating room for improvement.
This study has several limitations. First, the survey re-
sponse rate was lower than in the two previous surveys of
colony-stimulating factors (7,8), and was most likely re-
lated to the short period for conducting the survey. A
follow-up survey of erythropoietin use is planned to fol-
low the recent publication of evidence-based guidelines
(13), and a higher response rate is anticipated because
respondents will have 4 to 6 months to respond. Indeed,
prior surveys with relatively long response periods and a
series of follow-up telephone calls (8,9,18) have response
rates that are notably greater than those in surveys with
shorter response periods (7). Second, we assessed actual
practice patterns of erythropoietin prescription only in
one of the five disease settings described in the survey—
ovarian cancer. Third, several differences between the
clinical trial and the survey limit direct comparison, such
as the unit of analysis, which was at the physician level in
the survey and at the patient level in the clinical trial. In
the clinical trial, patients would commonly have one or
two anemic cycles before erythropoietin was prescribed.
In contrast, the survey assessed the physician’s maximum
tolerance before prescribing erythropoietin. Six percent
of physicians surveyed reported that they would never
prescribe erythropoietin; in the clinical trial, 62% of pa-
tients with grades 2 to 4 anemia were not treated with
erythropoietin. However, most physicians’ maximum
tolerance for erythropoietin prescription was at a hemo-
globin level10 g/dL, as was observed in the trial, where
hemoglobin level was often 9.5 g/dL when erythropoietin
was prescribed. Finally, evidence of a quality-of-life ben-
efit with erythropoietin was reported in a phase 3 trial
that was published following our survey and the publica-
tion of the clinical guidelines (17,19).
In conclusion, financial considerations and a hemo-
globin level10 g/dL appear to be the principal determi-
nants of erythropoietin use in the United States, as com-
pared with in other countries where financial
considerations alone appear to determine use. It would
be useful to re-evaluate the patterns of erythropoietin use
following the publication of the recent guidelines (17).
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APPENDIX
Summary of evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society
of Hematology*
1. The use of epoetin is recommended as a treatment option for patients with chemotherapy-associated anemia and a
hemoglobin concentration that has declined to a level10 g/dL. Red blood cell transfusion is also an option depending on the
severity of anemia or clinical circumstances.
2. For patients with declining hemoglobin levels but less severe anemia (hemoglobin level12 g/dL but10 g/dL), the decision
of whether to use epoetin immediately or to wait until hemoglobin levels fall closer to 10 g/dL should be determined by clinical
circumstances. Red blood cell transfusion is also a therapeutic option in severe clinical conditions.
3. The recommendations are based on evidence from trials in which epoetin was administered subcutaneously three times
weekly. The recommended starting dose is 150 U/kg given three times weekly for a minimum of 4 weeks, with consideration
given for dose escalation to 300 U/kg three times weekly for an additional 4 to 8 weeks in those who do not respond to the
initial dose. Although supported by less strong evidence, an alternative weekly dosing regimen (40,000 U per week), based on
common clinical practice, can be considered. Dose escalation of weekly regimens should be under similar circumstances to
thrice-weekly regimens.
4. Continuing epoetin treatment beyond 6 to 8 weeks in the absence of response (e.g., increase of1 to 2 g/dL in hemoglobin
level), assuming that appropriate dose increase has been attempted in nonresponders, does not appear to be beneficial. Patients
who do not respond should be investigated for underlying tumor progression or iron deficiency. As with other unsuccessful
treatments, consideration should be given to discontinuing the medication.
5. Hemoglobin levels can be raised to (or near) a concentration of 12 g/dL, at which time the dosage of epoetin should be titrated
to maintain that level or restarted when the level falls to near 10 g/dL. Insufficient evidence to date supports the
“normalization” of hemoglobin levels to above 12 g/dL.
6. Baseline and periodic monitoring of iron, total iron-binding capacity, transferrin saturation, or ferritin levels, and instituting
iron repletion when indicated, may be useful in limiting the need for epoetin, maximizing symptomatic improvement for
patients, and determining the reason for failure to respond to epoetin. There is inadequate evidence to specify the optimal
timing, periodicity, or testing regimen for such monitoring.
7. There is evidence from one well-designed, placebo-controlled, randomized trial that supports the use of epoetin in patients
with anemia associated with low-risk myelodysplasia, but there are no published high-quality studies to support its use in
patients with anemic myeloma, non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in the absence of chemotherapy.
Treatment with epoetin in myeloma, non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia patients experiencing
chemotherapy-associated anemia should follow the recommendations outlined above.
8. Physicians caring for patients with myeloma, non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia are advised to begin
treatment with chemotherapy or corticosteroids and to observe the hematologic outcomes achieved solely through tumor
reduction before considering epoetin. If a rise in hemoglobin level is not observed after chemotherapy, epoetin should be used
in accordance with the criteria outlined above for chemotherapy-associated anemia if clinically indicated. Blood transfusion is
also a therapeutic option.
* From Rizzo et al (17). Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical
Oncology and the American Society of Hematology. J Clin Oncol. 2002;20:4083– 4107. Reprinted with permission from the American Society of
Clinical Oncology.
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